AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: OCUL
Report Date: 2026-09-28
Full Report: https://amaly.io/stock/OCUL

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Ocular Therapeutix, Inc. (OCUL) is a clinical-stage biopharmaceutical company focused on ophthalmic therapeutics, with a halal core business but financial screening challenges due to interest income exceeding thresholds. The company demonstrates strong debt management and no non-permissible business activities, but the 7.87% interest income ratio leads to non-compliance across major Shariah standards and indices. Purification is required for any dividends, and while trends show improvement, inclusion in Shariah indices remains absent. Investors may consider monitoring for further financial purification.

Primary Compliance Concerns:
- Interest income ratio of 7.87% exceeds 5% threshold across AAOIFI, MSCI, and S&P standards

Purification Requirement: 7.87%
Index Inclusion: Not included in any of the four major Shariah-compliant indices: S&P Dow Jones, MSCI Islamic, FTSE Shariah, or DJIM.

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 4.4%
Liquidity Ratio: 20.3%
Interest Income Ratio: 7.9%
Purification Required: 7.87%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2026-01-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-17T00:00:00Z

---
Full interactive report: https://amaly.io/stock/OCUL
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.